KENMORE, N.Y. — March 13, 2026 — Leads & Copy — Firefly Neuroscience, Inc. (NASDAQ: AIFF) announced research advancements using Resting EEG/Cognitive EEG (ERP) brain scans from its FDA-cleared Evoke System to potentially distinguish between the three main ADHD subtypes.
The subtypes are hyperactive and impulsive, inattentive, and combined. The company is an Artificial Intelligence (“AI”) company developing brain health solutions for patients with neurological and mental disorders.
Over 22 million Americans are diagnosed with ADHD. However, an objective biological marker for distinguishing between its three subtypes has remained elusive. Firefly’s AI-powered EEG/ERP technology may help identify a patient’s ADHD subtype, potentially complementing subjective symptom checklists with neural signal-based precision.
Subtype identification could change the clinical equation, as Firefly’s platform may help clinicians determine the most appropriate treatment type, inform dosage decisions, and potentially monitor whether an intervention is working. This breakthrough advances Firefly’s mission to build the world’s first EEG/ERP brain foundation model, being trained on a growing repository of over 191,000 brain scans.
ADHD represents a U.S. treatment market estimated at over $10 billion. The condition has historically been diagnosed without objective biological tools for subtype differentiation.
A diagnosis of adult ADHD is based upon meeting general symptoms-based criteria: symptoms should be present in two or more settings; symptoms should interfere with a person’s functioning in social, work, or school-related activities; symptoms cannot be better explained by another mental health condition; and symptoms should not only occur during the course of a psychotic disorder.
Healthcare professionals use the Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR) to distinguish between the three types of ADHD. According to the DSM-5, adult ADHD may be diagnosed as hyperactive and impulsive, inattentive, or combined.
Gil Issachar, Chief Technology Officer of Firefly, said that unmet need remains after a general diagnosis of ADHD has been made. He added that Firefly’s EEG/ERP platform can leverage subtype-specific biomarker profiles to inform personalized treatment recommendations and open the door to ongoing treatment monitoring.
Firefly’s methodology is supported by prior peer-reviewed research, including a study published in Frontiers in Psychiatry, demonstrating the diagnostic utility of EEG-based brain activity flow pattern analysis in ADHD patients.
Greg Lipschitz, Chief Executive Officer of Firefly, said that this discovery serves as another demonstration of how the company is harnessing the power of AI and EEG/ERP to potentially transform neuroscience and clinical development.
Firefly’s proprietary database consists of over 191,000 EEG/ERP brain scans, making it the world’s largest known standardized EEG/ERP repository. Firefly’s EEG-based, AI-driven, and FDA-510(k)-cleared brain analytics technology has the potential to revolutionize diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD.
Source: Firefly Neuroscience, Inc.
